The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy
Helicobacter pylori infection is a severe global health problem that is closely associated with acid-related diseases and gastric malignancies. Eradicating H. pylori is strongly recommended for lowering peptic ulcer recurrence and preventing gastric cancer. The current approved H. pylori eradication...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article PeerReviewed |
Language: | English English English English |
Published: |
MDPI Multidisciplinary Digital Publishing Institute
2020
|
Subjects: | |
Online Access: | http://repository.unair.ac.id/108523/1/5.%20The%20Potential%20Benefits%20of%20Vonoprazan%20as%20Helicobacter%20pylori%20Infection%20Therapy.pdf http://repository.unair.ac.id/108523/2/5.pdf http://repository.unair.ac.id/108523/3/5.%20The%20Potential%20Benefits%20of%20Vonoprazan%20as%20Helicobacter%20pylori%20Infection%20Therapy.pdf http://repository.unair.ac.id/108523/4/5.%20BUKTI%20KORESPONDENSI%20JURNAL%20Pharmaceuticals.pdf http://repository.unair.ac.id/108523/ https://www.mdpi.com/1424-8247/13/10/276/htm https://doi.org/10.3390/ph13100276 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universitas Airlangga |
Language: | English English English English |
id |
id-langga.108523 |
---|---|
record_format |
dspace |
spelling |
id-langga.1085232021-07-12T03:40:43Z http://repository.unair.ac.id/108523/ The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy Muhammad Miftahussurur Boby Pratama Putra Yoshio Yamaoka R Medicine (General) RC Internal medicine Helicobacter pylori infection is a severe global health problem that is closely associated with acid-related diseases and gastric malignancies. Eradicating H. pylori is strongly recommended for lowering peptic ulcer recurrence and preventing gastric cancer. The current approved H. pylori eradication regimen combines a proton pump inhibitor (PPI) with two antibiotics. Unfortunately, this regimen failed to meet expectations mostly due to antibiotic resistance and insufficient gastric acid suppression. Vonoprazan, a novel potassium-competitive acid blocker, showed promising results as a PPI replacement. Vonoprazan inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions and forming disulfide bonds with the cysteine molecule of H+/K+-ATPase. Vonoprazan has superior pharmacological characteristics over PPI, such as no requirement for acid activation, stability in acidic conditions, shorter optimum acid suppression period, and resistance to cytochrome P (CYP)2C19 polymorphism. Several comparative randomized controlled trials and meta-analyses revealed the superiority of vonoprazan in eradicating H. pylori, notably the resistant strains. The adverse effect caused by vonoprazan is long-term acid suppression that may induce elevated gastrin serum, hypochlorhydria, and malabsorption. All vonoprazan studies have only been conducted in Japan. Further studies outside Japan are necessary for universally conclusive results. MDPI Multidisciplinary Digital Publishing Institute 2020-09 Article PeerReviewed text en http://repository.unair.ac.id/108523/1/5.%20The%20Potential%20Benefits%20of%20Vonoprazan%20as%20Helicobacter%20pylori%20Infection%20Therapy.pdf text en http://repository.unair.ac.id/108523/2/5.pdf text en http://repository.unair.ac.id/108523/3/5.%20The%20Potential%20Benefits%20of%20Vonoprazan%20as%20Helicobacter%20pylori%20Infection%20Therapy.pdf text en http://repository.unair.ac.id/108523/4/5.%20BUKTI%20KORESPONDENSI%20JURNAL%20Pharmaceuticals.pdf Muhammad Miftahussurur and Boby Pratama Putra and Yoshio Yamaoka (2020) The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals, 13 (10). pp. 1-14. ISSN 1424-8247 https://www.mdpi.com/1424-8247/13/10/276/htm https://doi.org/10.3390/ph13100276 |
institution |
Universitas Airlangga |
building |
Universitas Airlangga Library |
continent |
Asia |
country |
Indonesia Indonesia |
content_provider |
Universitas Airlangga Library |
collection |
UNAIR Repository |
language |
English English English English |
topic |
R Medicine (General) RC Internal medicine |
spellingShingle |
R Medicine (General) RC Internal medicine Muhammad Miftahussurur Boby Pratama Putra Yoshio Yamaoka The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy |
description |
Helicobacter pylori infection is a severe global health problem that is closely associated with acid-related diseases and gastric malignancies. Eradicating H. pylori is strongly recommended for lowering peptic ulcer recurrence and preventing gastric cancer. The current approved H. pylori eradication regimen combines a proton pump inhibitor (PPI) with two antibiotics. Unfortunately, this regimen failed to meet expectations mostly due to antibiotic resistance and insufficient gastric acid suppression. Vonoprazan, a novel potassium-competitive acid blocker, showed promising results as a PPI replacement. Vonoprazan inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions and forming disulfide bonds with the cysteine molecule of H+/K+-ATPase. Vonoprazan has superior pharmacological characteristics over PPI, such as no requirement for acid activation, stability in acidic conditions, shorter optimum acid suppression period, and resistance to cytochrome P (CYP)2C19 polymorphism. Several comparative randomized controlled trials and meta-analyses revealed the superiority of vonoprazan in eradicating H. pylori, notably the resistant strains. The adverse effect caused by vonoprazan is long-term acid suppression that may induce elevated gastrin serum, hypochlorhydria, and malabsorption. All vonoprazan studies have only been conducted in Japan. Further studies outside Japan are necessary for universally conclusive results. |
format |
Article PeerReviewed |
author |
Muhammad Miftahussurur Boby Pratama Putra Yoshio Yamaoka |
author_facet |
Muhammad Miftahussurur Boby Pratama Putra Yoshio Yamaoka |
author_sort |
Muhammad Miftahussurur |
title |
The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy |
title_short |
The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy |
title_full |
The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy |
title_fullStr |
The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy |
title_full_unstemmed |
The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy |
title_sort |
potential benefits of vonoprazan as helicobacter pylori infection therapy |
publisher |
MDPI Multidisciplinary Digital Publishing Institute |
publishDate |
2020 |
url |
http://repository.unair.ac.id/108523/1/5.%20The%20Potential%20Benefits%20of%20Vonoprazan%20as%20Helicobacter%20pylori%20Infection%20Therapy.pdf http://repository.unair.ac.id/108523/2/5.pdf http://repository.unair.ac.id/108523/3/5.%20The%20Potential%20Benefits%20of%20Vonoprazan%20as%20Helicobacter%20pylori%20Infection%20Therapy.pdf http://repository.unair.ac.id/108523/4/5.%20BUKTI%20KORESPONDENSI%20JURNAL%20Pharmaceuticals.pdf http://repository.unair.ac.id/108523/ https://www.mdpi.com/1424-8247/13/10/276/htm https://doi.org/10.3390/ph13100276 |
_version_ |
1707053490754289664 |